Company: Blueprint Medicines Corp

BPMC

Stock Code:

Enter Stock Code:

This report provides insider trading pattern and statistics for "Blueprint Medicines Corp (BPMC)" . Please read important descriptions at the bottom of this report.

Register Free Insider Trade Email Alert for "Blueprint Medicines Corp (BPMC)" !



 

Analysis & Screening

Chart Screening Tool

  Transaction Date

  Filing Date

Start Date:

Select Start Date

End Date:

Select End Date

Trading History Screening Tool

Transaction Code:

Ownership:

Share Class:

Trade Price From:

to

Transaction History From June 21st, 2017 To July 21st, 2017 (Max 50 Records Displayed)

Filing Date

Trade Date

 

Insider Name

Event Code

Ownership

Trade Information

Holding % Change

Jul 07/17

Jul 05/17

Company Director Sell

LYNCH DANIEL

S

Direct ownership

Disposed -7,500 Common Stock at $55.06

-3.42%

Jul 07/17

Jul 05/17

CxO Buy

Haviland Kate

Chief Business Officer

M

Direct ownership

Acquired 7,265 Common Stock at $16.28

0.00%

Jul 07/17

Jul 05/17

CxO Sell

Haviland Kate

Chief Business Officer

S

Direct ownership

Disposed -4,313 Common Stock at $55.76

-59.37%

Jul 07/17

Jul 05/17

CxO Sell

Haviland Kate

Chief Business Officer

S

Direct ownership

Disposed -700 Common Stock at $54.75

-23.71%

Jul 07/17

Jul 05/17

CxO Sell

Haviland Kate

Chief Business Officer

S

Direct ownership

Disposed -700 Common Stock at $53.58

-31.08%

Jul 07/17

Jul 05/17

CxO Sell

Haviland Kate

Chief Business Officer

S

Direct ownership

Disposed -700 Common Stock at $52.63

-45.10%

Jul 07/17

Jul 05/17

CxO Sell

Haviland Kate

Chief Business Officer

S

Direct ownership

Disposed -852 Common Stock at $51.54

-100.00%

Jul 07/17

Jul 05/17

CxO Sell

Haviland Kate

Chief Business Officer

M

Direct ownership

Disposed -7,265 Stock Option (Right to Buy)

-6.01%

Jun 30/17

Jun 28/17

First-Class Insider Sell

Albers Jeffrey W.

CEO and President

S

Direct ownership

Disposed -7,566 Common Stock at $51.21

-13.64%

Jun 30/17

Jun 28/17

First-Class Insider Sell

Albers Jeffrey W.

CEO and President

S

Direct ownership

Disposed -10,205 Common Stock at $50.22

-21.30%

Jun 30/17

Jun 28/17

First-Class Insider Sell

Albers Jeffrey W.

CEO and President

S

Direct ownership

Disposed -2,229 Common Stock at $49.10

-5.91%

Jun 30/17

Jun 28/17

CxO Buy

Haviland Kate

Chief Business Officer

M

Direct ownership

Acquired 6,357 Common Stock at $16.28

0.00%

Jun 30/17

Jun 28/17

CxO Sell

Haviland Kate

Chief Business Officer

S

Direct ownership

Disposed -6,357 Common Stock at $50.00

-100.00%

Jun 30/17

Jun 28/17

CxO Sell

Haviland Kate

Chief Business Officer

M

Direct ownership

Disposed -6,357 Stock Option (Right to Buy)

-4.99%

Jun 30/17

Jun 28/17

Company Director Sell

LYNCH DANIEL

S

Direct ownership

Disposed -3,125 Common Stock at $49.09

-1.40%

Jun 30/17

Jun 28/17

Company Director Sell

LYNCH DANIEL

S

Direct ownership

Disposed -21,474 Common Stock at $50.12

-8.80%

Jun 30/17

Jun 28/17

CxO Buy

Boral Anthony L.

Chief Medical Officer

M

Direct ownership

Acquired 10,000 Common Stock at $8.80

0.00%

Jun 30/17

Jun 28/17

CxO Sell

Boral Anthony L.

Chief Medical Officer

S

Direct ownership

Disposed -4,586 Common Stock at $51.08

-45.86%

Jun 30/17

Jun 28/17

CxO Sell

Boral Anthony L.

Chief Medical Officer

S

Direct ownership

Disposed -4,314 Common Stock at $50.19

-79.68%

Jun 30/17

Jun 28/17

CxO Sell

Boral Anthony L.

Chief Medical Officer

S

Direct ownership

Disposed -1,100 Common Stock at $49.07

-100.00%

Jun 30/17

Jun 28/17

CxO Sell

Boral Anthony L.

Chief Medical Officer

M

Direct ownership

Disposed -10,000 Stock Option (Right to Buy)

-5.28%

Jun 30/17

Jun 28/17

Company Director Sell

LYNCH DANIEL

S

Direct ownership

Disposed -7,901 Common Stock at $51.17

-3.14%

Jun 23/17

Jun 21/17

Company Director Buy

Demetri George

A

Direct ownership

Acquired 10,909 Stock Option (Right to Buy)

23.53%

Jun 23/17

Jun 21/17

Company Director Buy

Lydon Nicholas

A

Direct ownership

Acquired 10,909 Stock Option (Right to Buy)

100.00%

Jun 23/17

Jun 21/17

Company Director Buy

Rowland Charles A Jr

A

Direct ownership

Acquired 10,909 Stock Option (Right to Buy)

33.33%

Jun 23/17

Jun 21/17

Company Director Buy

Seely Lynn

A

Direct ownership

Acquired 10,909 Stock Option (Right to Buy)

33.33%

Jun 23/17

Jun 21/17

Company Director Buy

LYNCH DANIEL

A

Direct ownership

Acquired 10,909 Stock Option (Right to Buy)

100.00%

Jun 23/17

Jun 21/17

Company Director Buy

Goldberg Mark Alan

A

Direct ownership

Acquired 10,909 Stock Option (Right to Buy)

33.33%

Jun 23/17

Jun 21/17

Company Director Buy

COATS LONNEL

A

Direct ownership

Acquired 10,909 Stock Option (Right to Buy)

33.33%

Jun 23/17

Jun 21/17

Company Director Buy

Borisy Alexis

A

Direct ownership

Acquired 10,909 Stock Option (Right to Buy)

100.00%

Company: Blueprint Medicines Corp

BPMC

Stock Code:

Chart and trading summary tables represent transactions by company directors, chief executives(CEO, CFO, and senior company officers), corporate substantial shareholders, director's/executive's interest in affiliates of listed corporates, and individual substantial shareholders. Data on this page include all "Blueprint Medicines Corp (BPMC)" securities traded or transferred within the specified date range defined in stock screening and analysis panel beside the chart. (Note that, not all corporate insiders will record their trading price or number of shares bought/sold in their filings. The missing data are not included in the trading summary calculation). Different insider symbols in the price chart represent transaction activities on a particular date (Not Stock Trading Price). Additionally, transaction price in chart and trading summary table are adjusted for foreign currency exchange rate on the best efforts. The trading summary in net stock buying or stock selling totals are done on a best efforts basis. All data presented should be treated as estimates as it is based on insider trade filings which are subject to errors if input mistakes are made by a filers. Mouse over on signals to see the transaction details in the transaction info box. The chart is optimized for IE5 or above.

Disclaimer

InsidersLab.com focuses on tracking and monitoring insider trading activities in the US stocks market. "Insider Trading" means trading activities created by company directors, senior officers, individual substantial shareholders, and institutional shareholders. InsidersLab.com does not represent, warrant, nor endorse the accuracy, reliability, completeness or timeliness of any of the information, content, views, opinions, recommendations or advertisements (collectively, the "Materials") contained on, distributed through, or linked, downloaded or accessed from any of the services contained on the website (the "Service"), nor the quality of any products, information or other materials displayed, purchased, or obtained by you as a result of an advertisement or any other information or offer in or in connection with the Service (the "Products"). InsidersLab.com collects insider trading information from different public sources such as newspapers, financial information websites, and government statistics publications. You hereby acknowledge that any reliance upon any Materials shall be at your sole risk. In particular, none of the Materials is provided on the InsidersLab.com website or emails with a view to inviting, inducing or encouraging any person to make any kind of investment decision. Securities or other investments referred to in the Materials may not be suitable for you and you should not make any kind of investment decision in relation to them without first obtaining independent investment advice from a person authorized to give it.